CEOCFO Magazine has interviewed Aclipse Therapeutics CEO Raymond Houck. Mr. Houck has introduced the background of the company and our lead drug product M102. He has also described the target pathomechanisms of M102 and its precision medicine approach to ALS and CNS diseases.
Aclipse Therapeutics Announces $2.2 Million Grant from UK’s Medical Research Council for Development of M102
Funding Supports Aclipse Therapeutics’ and Sheffield Institute of Translational Neuroscience’s Development of M102 in Amyotrophic Lateral Sclerosis Radnor, PA —